IDH2 and chondrosarcoma: Using a more-complex chondrosarcoma culture model, we confirmed the sensitivity of chondrosarcoma to talazoparib monotherapy, irrespective of the IDH mutation status, although multiple dosing and longer treatment regimens were required.